T. Rowe Price Investment Management’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-5,162
| Closed | -$208K | – | 746 |
|
|
2026
Q1 | $208K | Buy |
5,162
+3,188
| +161% | +$68.7K | ﹤0.01% | 641 |
|
|
2025
Q4 | $50K | Sell |
1,974
-46,782
| -96% | -$1.1M | ﹤0.01% | 667 |
|
|
2025
Q3 | $1.1M | Sell |
48,756
-552
| -1% | -$12.9K | ﹤0.01% | 634 |
|
|
2025
Q2 | $854K | Buy |
49,308
+1,595
| +3% | +$29.5K | ﹤0.01% | 629 |
|
|
2025
Q1 | $1.04M | Hold |
47,713
| – | – | ﹤0.01% | 614 |
|
|
2024
Q4 | $1.52M | Sell |
47,713
-2,937,559
| -98% | -$88.3M | ﹤0.01% | 595 |
|
|
2024
Q3 | $86.1M | Sell |
2,985,272
-1,063,140
| -26% | -$39.4M | 0.05% | 323 |
|
|
2024
Q2 | $155M | Sell |
4,048,412
-557,309
| -12% | -$25.2M | 0.1% | 205 |
|
|
2024
Q1 | $271M | Sell |
4,605,721
-1,697,863
| -27% | -$108M | 0.17% | 154 |
|
|
2023
Q4 | $377M | Sell |
6,303,584
-215,887
| -3% | -$11M | 0.25% | 113 |
|
|
2023
Q3 | $248M | Buy |
6,519,471
+880,596
| +16% | +$38.7M | 0.18% | 152 |
|
|
2023
Q2 | $514M | Sell |
5,638,875
-121,789
| -2% | -$10.5M | 0.35% | 86 |
|
|
2023
Q1 | $380M | Sell |
5,760,664
-81,996
| -1% | -$4.73M | 0.27% | 102 |
|
|
2022
Q4 | $302M | Buy |
5,842,660
+326,537
| +6% | +$17.3M | 0.23% | 117 |
|
|
2022
Q3 | $377M | Buy |
+5,516,123
| New | +$326M | 0.3% | 94 |
|
Other funds holding APLS
T. Rowe Price Investment Management's APLS Position: Q2 2026 in Review
T. Rowe Price Investment Management sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 5,162 shares — an estimated $208K sold.
T. Rowe Price Investment Management first reported a position in APLS in Q3 2022 and held it in 15 quarters. The position peaked at $514M in Q2 2023. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- T. Rowe Price Investment Management reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- T. Rowe Price Investment Management sold 5,162 Apellis Pharmaceuticals shares in Q2 2026, an estimated $208K.
- T. Rowe Price Investment Management first reported a position in Apellis Pharmaceuticals in Q3 2022 and held it in 15 quarters.
- T. Rowe Price Investment Management's Apellis Pharmaceuticals position peaked at $514M in Q2 2023.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on T. Rowe Price Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.